- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT04506151
Schlafoptimierung zur Verbesserung der glykämischen Kontrolle bei Erwachsenen mit Typ-1-Diabetes (SOPT)
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Studientyp
Einschreibung (Tatsächlich)
Phase
- Unzutreffend
Kontakte und Standorte
Studienorte
-
-
Illinois
-
Chicago, Illinois, Vereinigte Staaten, 60612
- University of Illinois Chicago
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Beschreibung
Einschlusskriterien:
- Erwachsene im Alter von 18-65 Jahren
- klinische Diagnose von Typ-1-Diabetes mindestens ein Jahr
- berichtete gewohnheitsmäßige Schlafvariabilität (1 Stunde/Woche oder mehr) oder Schlafdauer weniger als 6,5 Stunden/Nacht an Arbeits- oder Wochentagen (bestätigt durch Aktigrafie-Schlafüberwachung)
- ein Wunsch, den Schlaf zu verbessern
- ein Smartphone besitzen
Ausschlusskriterien:
- Schlaflosigkeit symptome
- mit hohem Risiko für obstruktive Schlafapnoe
- schwere Hypoglykämie-Episode in den letzten 6 Monaten (z. Bewusstseinsverlust)
- A1C größer als 10 %
- Wechselschicht oder Nachtschichtarbeit
- Verwendung von Schlafmitteln/Hilfsmitteln
- Nierenfunktionsstörung (geschätzte glomeruläre Filtrationsrate < 45 ml/min)
- signifikante aktuelle medizinische Morbiditäten (wie Herzinsuffizienz, Zirrhose, chronisch obstruktive Lungenerkrankung, die Sauerstoff erfordert, aktive Behandlung von Krebs, Depression, Schlaganfall mit neurologischen Defiziten in der Anamnese).
- stillen, schwanger sind oder eine Schwangerschaft planen
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Doppelt
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Experimental: Schlaf-Opt
12-wöchige Intervention, die Selbstüberwachung, Zielsetzung und Motivationssteigerung umfasst.
|
12-wöchige Verhaltensintervention
|
|
Aktiver Komparator: Gesund leben
12-wöchige Intervention, die wöchentlichen telefonischen Kontakt, zeitlich gleiche didaktische Inhalte und Aufmerksamkeit für die Interventionsgruppe umfasst.
|
Gesund leben
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Sleep Variability Week 6
Zeitfenster: Week 6
|
Standard deviation total sleep time for one week
|
Week 6
|
|
Sleep Variability Week 12
Zeitfenster: Week 12
|
Standard deviation total sleep time for one week
|
Week 12
|
|
Sleep Variability Week 24
Zeitfenster: Week 24
|
Standard deviation total sleep time for one week
|
Week 24
|
|
Sleep Duration Week 6
Zeitfenster: Weeks 6
|
total sleep time minutes
|
Weeks 6
|
|
Sleep Duration Week 12
Zeitfenster: Week 12
|
total sleep time in minutes
|
Week 12
|
|
Sleep Duration Week 24
Zeitfenster: Week 24
|
total sleep time in minutes
|
Week 24
|
|
HbA1C Week 6
Zeitfenster: Week 6
|
Hemoglobin A1C week 6, %
|
Week 6
|
|
HbA1C Week 12
Zeitfenster: Week 12
|
HbA1c blood test
|
Week 12
|
|
HbA1C Week 24
Zeitfenster: Week 24
|
HbA1c blood test
|
Week 24
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Diabetes Distress Week 6
Zeitfenster: Week 6
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 6
|
|
Diabetes Distress Week 12
Zeitfenster: Week 12
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 12
|
|
Diabetes Distress Week 24
Zeitfenster: Week 24
|
Type 1 Diabetes Distress Scale measures diabetes distress.
Item mean scores calculated (sum of scores/number of items) ranges from 1-6 Higher scores indicated greater distress Unit of measure = units on a scale
|
Week 24
|
|
Self-management Behavior Week 6
Zeitfenster: Week 6
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 6
|
|
Self Management Behavior Week 12
Zeitfenster: Week 12
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Scores ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 12
|
|
Self Management Behavior Week 24
Zeitfenster: Week 24
|
Diabetes Self Management Questionnaire-R (DSMQ-R) measures diabetes self-management Item mean scores calculated (sum of scores/maximum possible sum of items * 10).
Ranges from 0-10.
Higher numbers indicate better self-management behavior Unit of measure = units on a scale
|
Week 24
|
|
Quality of Life Week 6
Zeitfenster: Week 6
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale |
Week 6
|
|
Quality of Life Week 12
Zeitfenster: Week 12
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale. |
Week 12
|
|
Quality of Life Week 24
Zeitfenster: Week 24
|
Diabetes Quality of Life scale measures quality of life Total quality of life score calculated as follows: (Raw total score - lowest possible score)/raw score range * 100. Scores range from 0-100. Scores are reverse coded so that higher numbers indicate better quality of life. Unit of measure = units on a scale. |
Week 24
|
|
Fatigue Week 6
Zeitfenster: Week 6
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 6
|
|
Fatigue Week 12
Zeitfenster: Week 12
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 12
|
|
Fatigue Week 24
Zeitfenster: Week 24
|
Patient Reported Outcomes Measure (PROMIS) fatigue scale score measures fatigue. The total score was converted to T-scores (with T-scores, 50 indicates the population mean with a standard deviation of 10). Mean T-scores were calculated. Higher scores reflect greater fatigue. |
Week 24
|
|
Mood Week 6
Zeitfenster: Week 6
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 6
|
|
Mood Week 12
Zeitfenster: Week 12
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 12
|
|
Mood Week 24
Zeitfenster: Week 24
|
Center for Epidemiological Studies-Depression (CES-D) measures depressive mood.
Total summed score ranges from 0-60.
Higher scores indicate greater depressive mood.
Unit of measure = units on a scale.
|
Week 24
|
|
Subjective Sleep Quality Week 6
Zeitfenster: Week 6
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 6
|
|
Subjective Sleep Quality Week 12
Zeitfenster: Week 12
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 12
|
|
Subjective Sleep Quality Week 24
Zeitfenster: Week 24
|
Pittsburgh Sleep Quality Index (PSQI) measures subjective sleep quality.
Total summed score ranges 0-21.
Higher score reflects poorer sleep quality.
Unit of measure = units on a scale.
|
Week 24
|
|
Glycemic Variability Week 6
Zeitfenster: Week 6
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 6
|
|
Glycemic Variability Week 12
Zeitfenster: Week 12
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 12
|
|
Glycemic Variability Week 24
Zeitfenster: Week 24
|
Coefficient of variation (CV%), continuous glucose monitoring (CGM)-derived glucose standard deviation (SD) divided by the mean and multiplied by 100.
|
Week 24
|
|
Glucose Time-in-range Week 6
Zeitfenster: Week 6
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 6
|
|
Glucose Time-in-range Week 12
Zeitfenster: Week 12
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 12
|
|
Glucose Time-in-range Week 24
Zeitfenster: Week 24
|
Percent of time continuous glucose monitoring (CGM)-derived glucose is between 70-180 mg/dL.
|
Week 24
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Tests of the Sleep Intervention Effect on A1C That is Due to the Change in Sleep Duration
Zeitfenster: week 12
|
Mediation tests of the sleep intervention effect on A1C that is due to the change in sleep duration.
It is the product of parameter estimates testing the effect of the intervention on sleep duration and the mediating effect of the change in sleep duration on A1C.
Markov chain Monte Carlo (MCMC) models were used.
|
week 12
|
|
Mediation Tests of the Sleep Intervention Effect on A1C That is Due to the Change in Sleep Variability.
Zeitfenster: Week 12
|
Results are not reported by treatment arm.
This analysis tests the sleep intervention effect on A1C that is mediated by the change in sleep variability.
The values reported are the product of parameter estimates testing the effect of the intervention on sleep variability and the effect of the change in sleep variability on A1C.
Markov chain Monte Carlo (MCMC) models were used.
|
Week 12
|
Mitarbeiter und Ermittler
Ermittler
- Hauptermittler: Pamela Martyn-Nemeth, PhD, University of Illinois at Chicago
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Martyn-Nemeth P, Duffecy J, Quinn L, Reutrakul S, Steffen AD, Burke L, Clark Withington MH, Irsheed GA, Perez R, Park M, Saleh A, Mihailescu D, Baron KG. Sleep optimization to improve glycemic control in adults with type 1 diabetes: study protocol for a randomized controlled parallel intervention trial. Trials. 2022 Aug 19;23(1):686. doi: 10.1186/s13063-022-06565-6.
- Hong SJ, Pratuangtham S, Martyn-Nemeth P, Steffen AD, Park CG, Reutrakul S. Blue Light Exposure During Sleep in Type 1 Diabetes: Impacts on Glycemic Control and Psychosocial Health. J Sleep Res. 2026 Jun 5:e70380. doi: 10.1111/jsr.70380. Online ahead of print.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 2020-0374
- 1R01DK121726 (US NIH Stipendium/Vertrag)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .